Therapies for the prevention of stroke and other vascular events in atrial fibrillation and atrial flutter

Canadian Journal of Cardiology

Volumn 21, Issue SUPPL. B, 2005, Pages

  Connolly, Stuart J ^a   Gillis, Anne M ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Acetylsalicylic acid; Anticoagulation; Atrial fibrillation; Prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; META ANALYSIS; RISK FACTOR; STROKE; SYSTEMATIC REVIEW; VASCULAR DISEASE;

ATRIAL FIBRILLATION; ATRIAL FLUTTER; CEREBROVASCULAR ACCIDENT; HUMANS; PRACTICE GUIDELINES; VASCULAR DISEASES;

EID: 34247384062     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framington Study. Stroke 1991;22:983-8.
2. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317:669-74.
3. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
4. Connolly SJ, Turpie AG. Antithrombotic therapy in atrial fibrillation. Can J Cardiol 1996;12(Suppl A):17A-20A.
5. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579S-89S.
6. Murgatroyd FD, Gibson SM, Baiyan X, et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation 1999;99:2765-70.
7. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999;131:492-501.
8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
9. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in non-valvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002;288:2441-8.
10. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
11. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-73.
12. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998;352:1167-71.
13. Olsson SB; Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 2003;362:1691-8.
14. Cleland JG, Freemantle N, Kaye G, et al. Clinical trials update from the American Heart Association meeting: Omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Fail 2004;6:109-15.
15. Klein AL, Grimm RA, Murray RD, et al; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20.